94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Erin D. Lewis1†
Edwin F. Ortega1
Maria Carlota Dao1
Kathryn Barger1
Joel B. Mason1
John M. Leong2
Marcia S. Osburne2Loranne Magoun2
Felix J. Nepveux V2Athar H. Chishti3Christopher Schwake3Anh Quynh3Cheryl H. Gilhooly1
Gayle Petty1
Weimin Guo1†Gregory Matuszek1Dora Pereira4†
Manju Reddy5
Jifan Wang1
Dayong Wu1
Simin N. Meydani1*Gerald F. Combs Jr.1- 1Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, United States
- 2Department of Molecular Biology and Microbiology, Tufts University, Boston, MA, United States
- 3Department of Developmental, Molecular and Chemical Biology, Tufts University, Boston, MA, United States
- 4Department of Pathology, University of Cambridge, Cambridge, United Kingdom
- 5Department of Food Science and Human Nutrition, Iowa State University, Ames, IA, United States
A corrigendum on
Safe and effective delivery of supplemental iron to healthy adults: a two-phase, randomized, double-blind trial – the safe iron study
by Lewis, E. D., Ortega, E. F., Dao, M. C., Barger, K., Mason, J. B., Leong, J. M., Osburne, M. S., Magoun, L., Nepveux, V. F. J., Chishti, A. H., Schwake, C., Quynh, A., Gilhooly, C. H., Petty, G., Guo, W., Matuszek, G., Pereira, D., Reddy, M., Wang, J., Wu, D., Meydani, S. N., and Combs, G. F. (2023). Front. Nutr. 10:1230061. doi: 10.3389/fnut.2023.1230061
In the published article, there was an error. The error involved an inconsistency between our abstract and discussion regarding the observed effects of one treatment on some secondary outcomes, GI symptoms.
A correction has been made to Abstract, subsection Results.
This section previously stated:
“Supplementation with any form of iron did not affect any primary endpoint. In Phase I, the frequency of gastrointestinal symptoms associated with FS was unaffected by dosing with MNP or weekly administration; but participants taking IHAT more frequently reported abdominal pain (27%, p < 0.008) and nausea (4%, p = 0.009) than those taking FS, while those taking ASP more frequently reported nausea (8%, p = 0.009). Surprisingly, only 9% of participants taking IHAT at 120 mg Fe/day (Phase II) reported abdominal pain and no other group reported that symptom.”
The corrected section appears below:
“Supplementation with any form of iron did not affect any primary endpoint. Regarding secondary endpoints, in Phase I participants taking IHAT more frequently reported abdominal pain (27%, p = 0.008) than other iron forms; those taking the weekly FS dose more frequently reported nausea (20%, P = 0.009) than the other forms and modes of administration. In phase II, no such differences were observed.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: iron, ferrous sulfate, malarial infectivity, bacterial proliferation, gut inflammation, IHAT, fungal iron
Citation: Lewis ED, Ortega EF, Dao MC, Barger K, Mason JB, Leong JM, Osburne MS, Magoun L, Nepveux V FJ, Chishti AH, Schwake C, Quynh A, Gilhooly CH, Petty G, Guo W, Matuszek G, Pereira D, Reddy M, Wang J, Wu D, Meydani SN and Combs GF Jr (2024) Corrigendum: Safe and effective delivery of supplemental iron to healthy adults: a two-phase, randomized, double-blind trial – the safe iron study. Front. Nutr. 11:1376599. doi: 10.3389/fnut.2024.1376599
Received: 25 January 2024; Accepted: 12 February 2024;
Published: 27 February 2024.
Edited and reviewed by: Johannes le Coutre, University of New South Wales, Australia
Copyright © 2024 Lewis, Ortega, Dao, Barger, Mason, Leong, Osburne, Magoun, Nepveux V, Chishti, Schwake, Quynh, Gilhooly, Petty, Guo, Matuszek, Pereira, Reddy, Wang, Wu, Meydani and Combs. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Simin N. Meydani, c2ltaW4ubWV5ZGFuaUB0dWZ0cy5lZHU=
†Present addresses: Erin D. Lewis, KGK Science, Inc., London, Ontario, ON, Canada
Weimin Guo, Department of Pathology and Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, United States
Dora Pereira, Vifor Pharma UK Ltd., Cambridge, England, United Kingdom